CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations

Official title

A Multicenter Hybrid Platform Trial Comparing the Effects of a Prospective Cohort Treated With a Tri- Layer Amnion Graft or a Single Layer Amnion Graft to a Coarsened Exact Matched Retrospective Control Cohort of Patients With Hard-to-heal DFUs and VLUs

Overview

CAMP RWE Trial: A Multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a tri-layer amnion graft or a single layer amnion graft to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs

Detailed description

A multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a tri layer amnion graft or a single layer amnion graft to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs

Hybrid prospective platform 2 arm, comparative, randomized multicenter study with a CSM matched retrospective control group Interventional comparative study

* IP 1: BioLab Membrane Wrap Lite * IP2: BioLab Tri-Membrane Wrap

Standard of care: Debridement, maintenance of proper moisture balance, reduction in bacterial burden, offloading and multilayer compression.

Patients with nonhealing venous leg ulcerations or diabetic foot ulcers of at least 4-weeks duration that have failed to show 50% PAR with SOC therapies Patients receiving SOC therapies for hard-to-heal VLUs and/or DFUs

To gather prospective real-world evidence (RWE) in both diabetic foot ulcers and venous leg ulcers increasing the understanding of treatment performance in everyday clinical settings, capturing insights from a more diverse patient population than traditional clinical trials. This information is vital for evaluating the effectiveness of innovative wound care strategies in practical, real-life scenarios

To demonstrate the clinical effectiveness of IP1 and IP2 as an adjunct to standard of care in supporting wound healing compared to standard of care alone in venous leg ulcers and diabetic foot ulcers across the continuum of care.

Interventions

• Other IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap
  BioLab Membrane Wrap LiteTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Membrane Wrap LiteTM is a single-layer human tissue allograft, containing solely the amnion layer of Amniotic Membrane \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.
• Other IP2: BioLab Tri-Membrane Wrap
  BioLab Tri-Membrane WrapTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Tri-Membrane WrapTM is a triple-layered human tissue allograft, containing amnion-chorion-amnion layers \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.

Primary outcome measures

• Wound Closure [Time frame: 12 Weeks]

Secondary outcome measures (1)

• Wound percent area reduction [Time frame: Weeks 4, 8, and 12]

Eligibility criteria

Inclusion criteria

• Male or female 18 years of age and older
• 2\. Subjects having a non-healing venous leg ulcer or diabetic foot ulcer of >4 weeks duration and visible signs of healing objectively, less than 50% reduction in wound size in the last 4 weeks
• Subjects' wound size is minimum of 2 cm2 and maximum of 25cm2
• If the subject has more than one eligible wound the largest wound will be selected (the index wound)
• Subject is able and willing to follow the protocol requirements
• Subject has signed informed consent

Exclusion criteria

• Inability to adhere to the study protocol or study visit schedule
• Pregnancy
• Child-bearing potential without appropriate contraception
• Lactation
• Treatment of the wound with engineered tissue or other scaffold materials within 30 days preceding the first treatment visit.
• Visible signs of improvement in the four weeks before randomisation (defined objectively as a 50% reduction in surface area in the four weeks before enrolment)
• The subject has other concurrent conditions that in the opinion of the investigator may compromise subject safety
• Known contraindications to the use of amniotic tissue grafts
• The index ulcer shows clinical signs and symptoms of wound infection needing treatment with local or systemic antimicrobials or antibiotics

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 7 centers

• FOMAT Medical Research — Oxnard
• Solutions Medical Research — Coral Gables
• Nova Medical Services - Research Division LLC — Miami
• Indiana University Health Methodist Hospital — Indianapolis
• St. Louis Foot and Ankle, LLC — St Louis
• Jevlos Health, Inc — Syosset
• Hope Vascular and Podiatry — Houston

Identifiers

NCT: NCT07046767 · CAMP RWE

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗